Lixte rises after buying UK firm to enter proton therapy cancer care

NOMAD Power Solutions

25/11/2025 13:53

** Shares of drug developer Lixte Biotechnology LIXT.O rise 7% to $4.78 premarket

** Co says it acquired Liora Technologies Europe, which develops proton therapy systems for cancer treatment

** Liora's flagship "LiGHT System" aims to deliver high-precision proton therapy at lower cost and fewer sessions - LIXT

** LIXT says system installed at UK's STFC Daresbury Lab; plans to create a center of excellence for cancer care

** Deal expands co beyond cancer drugs into radiotherapy; complements trials of its cancer therapy LB-100 for ovarian and colon cancer

** Proton therapy is a type of radiation treatment for cancer that uses protons instead of X-rays to target tumors

** Up to last close, stock up ~120% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))